Trial Profile

A Single-Arm, Expanded Access Study of Zanubrutinib (BGB3111) in Participants With B-cell Malignancies

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2023 Results of pooled analysis from (BGB-3111-AU-003, BGB-3111-215, BGB-3111-216, BGB-3111-1002,BGB-3111-GA-101) assessing comparative summary of safety and efficacy data between the QD and BID regimens in patients with various B-cell malignancies presented at the 28th Congress of the European Haematology Association
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
27 Apr 2022 According to a BeiGene media release, data from this trial will be presented at the 2022 Annual Meeting of the American Society of Cancer Oncology (ASCO) (Abstract Number: e19522)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com